PAR-2 has been shown to be expressed, amongst others, on fibroblasts and HSCs, and thus, in addition to tryptase inhibitors, PAR-2 antagonists might be beneficial in the treatment of liver fibrosis. This evidence concerns the gene F2RL1 and Hepatic fibrosis.